BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Egalet to Present at Life Sciences Europe Conference


5/18/2012 10:07:46 AM

MALVERN, Pa., May 17, 2012 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today Bob Radie, president and chief executive officer (CEO), will present at the Life Sciences Europe conference on May 23 organized by the International Venture Club. Mr. Radie will review the company's patented technology and pipeline of abuse-deterrent opioids that are nearing phase 3.

About Egalet Ltd.

Egalet Ltd. is a European-based specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners. Based on the proprietary technology, Egalet is developing a pipeline of abuse-deterrent opioids that are nearing pivotal testing. In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing.

Egalet has pioneered one of the world's first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet. In addition, the Egalet technology, a novel, patented drug delivery platform, was designed to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting. The uniquely shaped, patient-friendly tablet consists of matrix and can add a shell or coat. By altering the composition of the shell and matrix, a variety of extended-release formulations can be produced. The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids. Egalet has extensively filed patents to protect its inventions covering both the technology and product-specific patents. Please visit www.egalet.com for more information.

Contact:
E. Blair Schoeb
Tel.: 908-277-0386
Email: blair@biotechcomm.com

SOURCE Egalet Ltd.



Read at BioSpace.com

Egalet
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES